Jazz Pharmaceuticals PLC (JAZZ)

Return on equity (ROE)

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Net income (ttm)	US$ in thousands	560,120	463,159	394,924	330,794	414,832	80,727	-83,196	-152,969	-216,600	-12,000	-47,730	-445,711	-329,668	-160,903	40,164	518,281	238,616	179,194	133,236	280,333
Total stockholders’ equity	US$ in thousands	4,093,760	4,171,070	3,762,600	3,696,460	3,737,000	3,489,370	3,525,680	3,335,040	3,085,730	2,745,190	3,200,780	3,608,490	3,965,190	3,938,480	4,131,490	3,797,690	3,659,740	3,377,200	3,141,800	2,808,500
ROE		13.68%	11.10%	10.50%	8.95%	11.10%	2.31%	-2.36%	-4.59%	-7.02%	-0.44%	-1.49%	-12.35%	-8.31%	-4.09%	0.97%	13.65%	6.52%	5.31%	4.24%	9.98%

December 31, 2024 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $560,120K ÷ $4,093,760K
= 13.68%

Jazz Pharmaceuticals PLC's return on equity (ROE) has shown fluctuations over the past few quarters. The ROE was relatively stable at single-digit percentages in 2020, ranging from 4.24% to 13.65%. However, there was a significant decline in ROE in the following quarters, with negative ROE values recorded in the latter part of 2021 and extending into the first half of 2022.

From the second half of 2022 onwards, the company's ROE started to recover, turning positive again in September 2023. This positive trend continued into 2024, with ROE ranging from 8.95% to 13.68% in the last few quarters.

Overall, Jazz Pharmaceuticals PLC's ROE performance reflects periods of both strengths and weaknesses. It is crucial for investors and stakeholders to monitor the company's ROE closely to assess its profitability and efficiency in generating returns for shareholders.